Evidence map›Paper›PMID 26718214›Full record

ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2016

LKB1/AMPK inhibits TGF-β1 production and the TGF-β signaling pathway in breast cancer cells.

Nian-Shuang Li, Jun-Rong Zou, Hui Lin, Rong Ke, Xiao-Ling He, Lu Xiao, Deqiang Huang, Lingyu Luo, Nonghua Lv, Zhijun Luo

Open access · hybridAbstract read
In one paragraph

Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 54 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Metformin as a PotentialInternational journal of breast cancer · 2024
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. New and Emerging Targeted Therapies for Advanced Breast Cancer.International journal of molecular sciences · 2022
    Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Nian-Shuang LiResearch Institute of Digestive Diseases and Department of Gastroenterology, The First Affiliated Hospital, Nanchang University, Nanchang, Jiangxi, China.
Jun-Rong ZouResearch Institute of Digestive Diseases and Department of Gastroenterology, The First Affiliated Hospital, Nanchang University, Nanchang, Jiangxi, China.
Hui LinGraduate Program of Basic Medical Sciences, School of Basic Medical Sciences, Nanchang University, Nanchang, Jiangxi, China.
Rong KeGraduate Program of Basic Medical Sciences, School of Basic Medical Sciences, Nanchang University, Nanchang, Jiangxi, China.
Xiao-Ling HeGraduate Program of Basic Medical Sciences, School of Basic Medical Sciences, Nanchang University, Nanchang, Jiangxi, China.
Lu XiaoGraduate Program of Basic Medical Sciences, School of Basic Medical Sciences, Nanchang University, Nanchang, Jiangxi, China.
Deqiang HuangResearch Institute of Digestive Diseases and Department of Gastroenterology, The First Affiliated Hospital, Nanchang University, Nanchang, Jiangxi, China.
Lingyu LuoResearch Institute of Digestive Diseases and Department of Gastroenterology, The First Affiliated Hospital, Nanchang University, Nanchang, Jiangxi, China.
Nonghua LvResearch Institute of Digestive Diseases and Department of Gastroenterology, The First Affiliated Hospital, Nanchang University, Nanchang, Jiangxi, China. lunonghua@ncu.edu.cn.
Zhijun LuoGraduate Program of Basic Medical Sciences, School of Basic Medical Sciences, Nanchang University, Nanchang, Jiangxi, China. zluo@bu.edu.
Nanchang University · CNFirst Affiliated Hospital of Nanchang University · CN

Funding

AMPK regulates angiogenesis by inhibition of the ALK1 signaling pathwayR21EY024388 · NEI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI LUO, ZHIJUN · 2014 to 2015
$446k
NEI NIH HHS R21 EY024388
6 · The paper itself

Abstract

Adenosine monophosphate-activated protein kinase (AMPK) acts as a fuel gauge that maintains energy homeostasis in both normal and cancerous cells, and has emerged as a tumor suppressor. The present study aims to delineate the functional relationship between AMPK and transforming growth factor beta (TGF-β). Our results showed that expression of liver kinase B1 (LKB1), an upstream kinase of AMPK, impeded TGF-β-induced Smad phosphorylation and their transcriptional activity in breast cancer cells, whereas knockdown of LKB1 or AMPKα1 subunit by short hairpin RNA (shRNA) enhanced the effect of TGF-β. Furthermore, AMPK activation reduced the promoter activity of TGF-β1. In accordance, type 2 diabetic patients taking metformin displayed a trend of reduction of serum TGF-β1, as compared with those without metformin. A significant reduction of serum TGF-β1 was found in mice after treatment with metformin. These results suggest that AMPK inhibits the transcription of TGF-β1, leading to reduction of its concentration in serum. Finally, metformin suppressed epithelial-to-mesenchymal transition of mammary epithelial cells. Taken together, our study demonstrates that AMPK exerts multiple actions on TGF-β signaling and supports that AMPK can serve as a therapeutic drug target for breast cancer.

Indexed as

AgedAMP-Activated Protein Kinase KinasesAMP-Activated Protein KinasesAnimalsBlotting, WesternBreast NeoplasmsCell Line, TumorCell MovementEpithelial-Mesenchymal TransitionFemaleFluorescent Antibody TechniqueHumansHypoglycemic AgentsMaleMetforminMiceAMP-Activated Protein Kinase KinasesAMP-Activated Protein KinasesHypoglycemic AgentsMetforminProtein Serine-Threonine KinasesRNA, Small InterferingSTK11 protein, humanTransforming Growth Factor beta1AMPKBreast cancer cell migrationEpithelial-to-mesenchymal transitionLKB1TGF-β production and signaling

Identifiers

PMID26718214
PMCPMC4875963
OpenAlexW2276308812

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.